Colombo Delia, Chimenti Sergio, Grossi Paolo Antonio, Marchesoni Antonio, Bardazzi Federico, Ayala Fabio, Simoni Lucia, Vassellatti Donatella, Bellia Gilberto
Novartis Farma Italia, Origgio (VA), Varese, Italy.
Tor Vergata Polyclinic Rome, Varese, Italy.
Clin Cosmet Investig Dermatol. 2015 Dec 22;9:1-7. doi: 10.2147/CCID.S88306. eCollection 2016.
Sex medicine studies have shown that there are sex differences with regard to disease characteristics in immune-mediated inflammatory diseases, including psoriasis, in immune response and susceptibility to viral infections. We performed a post hoc analysis of the Observational Study of infectious events in psoriasis complicated by active psoriatic arthritis (SYNERGY) study in patients with psoriatic arthritis (PsA) treated with immunosuppressive regimens including cyclosporine, in order to evaluate potential between-sex differences in severity of disease and prevalence of viral infections.
SYNERGY was an observational study conducted in 24 Italian dermatology clinics, which included 238 consecutively enrolled patients with PsA, under treatment with immunosuppressant regimens including cyclosporin A. In this post hoc analysis, patients' demographical data and clinical characteristics of psoriasis, severity and activity of PsA, prevalence of seropositivity for at least one viral infection, and treatments administered for PsA and infections were compared between sexes.
A total of 225 patients were evaluated in this post hoc analysis, and 121 (54%) were males. Demographic characteristics and concomitant diseases were comparable between sexes. Statistically significant sex differences were observed at baseline in Psoriasis Area and Severity Index score (higher in males), mean number of painful joints, Bath Ankylosing Spondylitis Disease Activity Index, and the global activity of disease assessed by patients (all higher in females). The percentage of patients with at least one seropositivity detected at baseline, indicative of concomitant or former viral infection, was significantly higher among women than among men. No between-sex differences were detected in other measures, at other time points, and in treatments. Patients developed no hepatitis B virus or hepatitis C virus reactivation during cyclosporine treatment.
Our post hoc sex analysis suggests that women with PsA have a greater articular involvement and a higher activity of disease compared to males. Immunosuppressive treatment with cyclosporine seems not to increase susceptibility to new infections or infectious reactivations, with no sex differences.
性医学研究表明,在包括银屑病在内的免疫介导的炎症性疾病中,疾病特征、免疫反应以及对病毒感染的易感性方面存在性别差异。我们对银屑病合并活动性银屑病关节炎(SYNERGY)研究中接受包括环孢素在内的免疫抑制方案治疗的银屑病关节炎(PsA)患者的感染事件进行了事后分析,以评估疾病严重程度和病毒感染患病率方面潜在的性别差异。
SYNERGY是一项在24家意大利皮肤科诊所进行的观察性研究,纳入了238例连续入组的接受包括环孢素A在内的免疫抑制方案治疗的PsA患者。在这项事后分析中,比较了男女患者的人口统计学数据、银屑病的临床特征、PsA的严重程度和活动度、至少一种病毒感染血清阳性的患病率以及针对PsA和感染所给予的治疗。
在这项事后分析中共评估了225例患者,其中121例(54%)为男性。男女患者的人口统计学特征和伴发疾病具有可比性。在基线时,银屑病面积和严重程度指数评分(男性更高)、疼痛关节的平均数量、巴斯强直性脊柱炎疾病活动指数以及患者评估的疾病总体活动度方面观察到具有统计学意义的性别差异(均为女性更高)。基线时检测到至少一种血清阳性(表明存在合并或既往病毒感染)的患者百分比在女性中显著高于男性。在其他测量指标、其他时间点以及治疗方面未检测到性别差异。患者在环孢素治疗期间未出现乙型肝炎病毒或丙型肝炎病毒再激活。
我们的事后性别分析表明,与男性相比,PsA女性患者的关节受累更严重且疾病活动度更高。环孢素免疫抑制治疗似乎不会增加对新感染或感染再激活的易感性,且不存在性别差异。